[2] Immune stimulating antibody conjugates work by activating dendritic cells within the tumor,[3] and are capable of being delivered systemically.
[4] With some patients being resistant to checkpoint inhibitors, immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like receptors.
[3] In mice models, "dendritic cells (DCs) [were able] to internalize tumor antigens and subsequently activate tumor-reactive T cells"; this has been used "to treat autologous and autochthonous tumors successfully".
[5] An immune stimulating antibody conjugate comprising a TLR7/TLR8 dual agonist conjugated to antibodies targeting at human epidermal growth factor receptor 2(HER2) has been developed.
[6] Mechanically, immune stimulating antibody conjugates required tumor antigen recognition, FcγR-dependent phagocytosis and TLR-mediated activation to drive tumor killing by myeloid cells and subsequent T-cell-mediated antitumor immunity.